RxDoctor Payments Data

Sara Beeler, APRN

Oncology · Tampa, FLNPI 1720328198

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $265,690 of the $337,478 with a category attached, or 78.7%. AstraZeneca accounts for 78.9% of it on its own, with 59 other manufacturers making up the rest. Among oncology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$337,478in general payments, 2019–2025

Across 1,343 payments — averaging $251.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$266K
  • Daiichi Sankyo Inc.$55K
  • Novartis$3K
  • Gilead$1K
  • Johnson & Johnson$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • plus $11K from 54 others

What the payments were for

  • Consulting fees$9,2103%
  • Speaking & faculty fees$265,69079%
  • Travel & lodging$32,12010%
  • Food & beverage$29,3539%
  • Education$1230%
  • Other$9820%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)439$266,246
Daiichi Sankyo Inc.100$54,568
Novartis106$2,654
Gilead(2 entities)57$1,130
Johnson & Johnson60$1,077
E.r. Squibb & Sons, L.L.C.60$1,039
Bristol Myers Squibb44$896
Pfizer40$797
Incyte Corporation34$684
Merck34$664
Lilly USA, LLC29$495
AbbVie18$469
Eisai Inc.20$367
GSK16$353
Regeneron Healthcare Solutions, Inc.14$346
Astellas Pharma US Inc16$331
Puma Biotechnology, Inc.17$316
Seagen Inc.17$296
Bayer15$294
Sanofi14$277
Amgen15$277
Takeda Pharmaceuticals U.S.A., Inc.9$273
Tersera Therapeutics LLC9$249
Pharmacyclics LLC, An Abbvie Company10$237
Beigene USA, Inc.6$152
Exelixis Inc.5$147
Deciphera Pharmaceuticals Inc.7$146
Sumitomo Pharma America, Inc.8$136
Stemline Therapeutics Inc.6$129
Dendreon Pharmaceuticals LLC4$129
Taiho Oncology, Inc.7$118
Pharmaessentia USA Corporation5$118
Rigel Pharmaceuticals, Inc.4$113
Legend Biotech USA Inc.4$111
Karyopharm Therapeutics Inc.6$108
Genentech USA, Inc.6$104
Pharmacosmos Therapeutics Inc.5$98
AVEO Pharmaceuticals, Inc.5$98
Mirati Therapeutics, Inc.4$92
EMD Serono, Inc.4$88
Genmab U.S., Inc.4$85
Sobi, Inc5$79
Ipsen Biopharmaceuticals, Inc4$78
Jazz Pharmaceuticals Inc.4$76
Blueprint Medicines Corporation3$67
Boston Scientific3$65
Geron Corporation3$63
Array Biopharma Inc3$59
Myriad Genetic Laboratories, Inc.2$52
CTI Biopharma Corp.3$42
Agios Pharmaceuticals, Inc.2$38
GE HealthCare2$36
G1 Therapeutics, Inc.2$36
CSL Behring2$36
ADC Therapeutics America, Inc.1$33
Myovant Sciences Inc.2$32
Recordati_rare_diseases_inc.2$30
Immunocore Limited1$29
Boehringer Ingelheim1$29
TG Therapeutics, Inc.1$29

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$337,478 in reported general payments places this provider in the 95th percentile of 24 oncology providers in Florida.

See all oncology providers in Florida

Medicare billing

Part B allowed, 2024
$36,302
Medicare patients
33
Services billed
2,176

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide42$656,661
IbrancePalbociclib14$212,513
XtandiEnzalutamide11$181,018
EliquisApixaban54$35,820
XareltoRivaroxaban28$27,858
Letrozole232$6,208
Exemestane26$2,017
Anastrozole66$1,172
Tamoxifen Citrate21$777
Ondansetron OdtOndansetron35$602
Acyclovir34$368
Hydroxyurea17$206
Prochlorperazine Maleate16$125
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim32$115
Gabapentin13$108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$896$656,66142 claims
PfizerIbrance, Eliquis$797$248,33368 claims
Astellas Pharma US IncXtandi$331$181,01811 claims
Johnson & JohnsonXarelto$1,077$27,85828 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 24 oncology providers in Florida.

Other oncology in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →